Biocon reports Rs 42 crore net loss in Q3 due to exceptional item
The biggest contribution came from the biosimilars business, which reported a 54% increase in revenues to Rs 1,507 crore. Research Services revenues (Syngene) rose 23% YoY to Rs 786 crore and generics business revenues grew 18% YoY to Rs 718 crore.
